BridgeBio Signs Voluntary U.S. Government Agreement on Medicine Access and Pricing
BridgeBio entered a voluntary agreement with the U.S. government to expand Medicaid access to Attruby through the GENEROUS Model and lower drug costs. The company says it does not expect to be subject to future pricing mandates, and the specific terms remain confidential.
Key points
- Agreement expands state Medicaid access to Attruby via the GENEROUS Model; specific terms are confidential
- BridgeBio does not expect future pricing mandates; pricing commitments for future medicines are expected to exclude medicines approved exclusively for orphan indications
- ForgingBridges copay program is unaffected and can reduce out-of-pocket costs to as little as $0 per month
- Pending FDA reviews include BBP-418 (PDUFA November 27, 2026) and encaleret (PDUFA May 7, 2027)
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.